Eli Lilly and Company

Indiana University

Pisces Therapeutics, LLC

Other

Apexian Pharmaceuticals, Inc.

Apex Therapeutics, Inc.

James Howard Wikel

Charles J Paget, Jr

Michael Robert Wiley

Gerald Floyd Smith

Robert T Shuman

Jason Scott Sawyer

Douglas Wade Beight

Steven E Hall

John Joseph Masters

David Kent Herron

Ying Kwong Yee

Valentine Joseph Klimkowski

David Mendel

Jennifer Marie Tinsley

Anne Louise Tebbe

Trelia Joyce Craft

Leonard Crayton Weir

Jeffry Bernard Franciskovich

Guy Milot

Jeffrey Alan Kyle

Theodore Goodson, Jr

Sajan Joseph

James W Chamberlin

Marta Maria Pi&ntilde;eiro-N&uacute;&ntilde;ez

Mark R Kelley

Carl Penman Denny

Michael Jay Brownstein

Tina M Morwick

Theodore Goodson, Junior

Marta Maria Pi&ntilde;eiro-Nu&ntilde;ez

Timothy Alan Shepherd

Rosanne Bonjouklian

Aaron L Schacht

Chafiq Hamdouchi

Edward R Lavagnino

Robert Dean Dally

Alfonso De Dios

Marta Maria Pineiro-Nunez

Concepcion Sanchez-Martinez

Carlos Montero Salgado

Donald R Holland

Luisa Maria Martin-Cabrejas

Beatriz Lopez De Uralde Garmendia

Kenneth S Su

Carlos Jaramillo Aguado

Sheila Pleite Selgas

Lewis C Lappas

Miriam Filadelfa Del Prado Catalina

Jeremy Schulenberg York

Marta Maria Pinelro-Núnez

Jose Eugenio De Diego Gomez

Tiecho Li

Jeffrey Bernard Franciskovich

Michal Vieth

Theodore Goodson Jr

Leslie J Lorenz

Robert J Templeton

Guy Milet

Small molecule inhibitor compounds for inhibiting Rac1 activity and their use for treating, preventing, or reducing the incidences of malignant and nonmalignant manifestations, e.g., plexiform neurofibromas that occur in subjects suffering from neurofibromatosis type 1 (NF1) are disclosed.

RAC1 inhibitors of neurofibroma formation

The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.

Quinone compounds for treating APE1 mediated diseases

The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating mediated diseases.

Quinone compounds for treating Ape1 mediated diseases

The present disclosure describes new inhibitors or antagonists of Ras useful for the treatment of conditions resulting from Ras-induced or mediated cellular processes, including cellular proliferation, differentiation, apoptosis, senescence, and survival. These cellular processes may be associated with a non-malignant or malignant disease, disorder, or pathological condition. The present disclosure also describes a method for inhibiting such Ras-induced or mediated cellular processes. The method entails administering a Ras antagonist in an amount effective to inhibit such cellular processes.

Malignant and non-malignant disease treatment with Ras antagonists

The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis 

Benzimidazoles and benzothiazoles as inhibitors of map kinase

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Aromatic amides

Antithrombotic amides

This application relates to heteroaromatic amides (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Heteroroaromatic amides as inhibitor of factor Xa

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Antithrombotic agents

Growing community of inventors

Greenwood, IN, United States of America

James Howard Wikel